inner-banner

STARRT-AKI

ANZICS CTG Endorsed Study

STARRT-AKI

Standard versus accelerated initiation of renal replacement therapy in acute kidney injury

Study Description

To determine whether immediate initiation of renal replacement therapy (RRT), compared to delayed approach to RRT initiation, improves survival and renal recovery (RRT independence) at 90 days in critically ill patients with severe AKI.

Management Committee

Martin Gallagher (Chair), Sean Bagshaw, Rinaldo Bellomo, Heidi Buhr, Raulle Sol Cruz (Project Manager NZ), Erika Dempsey (Project Manager), Glenn Eastwood, David Gattas, Shay McGuinness, Rachael Parke, Andrew Udy, Ron Wald and Amanda Wang.

Administering Institution

The George Institute for Global Health, Australia (Renal and Metabolic Division)
Medical Research Institute of New Zealand

Collaborators

St Michael’s Hospital, Canadian Critical Care Trials Group
Medical Research Institute of New Zealand

Sample Size

3000 patients

Funding

St Michael’s Hospital (Start-up funds per contractual agreement) CAN$120,000
NHMRC $2.1 million
HRC NZ $1.19 million

Project Status as of June 2019

STARRT-AKI has recruited well globally and will likely stop recruiting by mid-August 2019, as we have reached more than 99% of the global recruitment target. Data collection will continue with a 3-month follow-up for the primary outcome concluding by 31 December 2019. The secondary outcomes, which include 1-year follow-up, will be sought via data linkage. The data linkage for secondary outcomes will occur in Q3 2020. This has been an extremely successful global collaboration with Australia and New Zealand sites contributing approximately 20% of the global study participants.

Contact

Rinaldo Bellomo (email)
Erika Dempsey (email)

Reference

CTG1516-02
NCT02568722